- Home
- TNXP vs ANIX Comparison
TNXP vs ANIX Comparison
Compare TNXP & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- ANIX
- Stock Information
- Founded
- TNXP 2007
- ANIX 1982
- Country
- TNXP United States
- ANIX United States
- Employees
- TNXP N/A
- ANIX N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- ANIX Biotechnology: Pharmaceutical Preparations
- Sector
- TNXP Health Care
- ANIX Health Care
- Exchange
- TNXP Nasdaq
- ANIX Nasdaq
- Market Cap
- TNXP 118.2M
- ANIX 84.7M
- IPO Year
- TNXP N/A
- ANIX 1987
- Fundamental
- Price
- TNXP $18.94
- ANIX $2.63
- Analyst Decision
- TNXP Strong Buy
- ANIX Strong Buy
- Analyst Count
- TNXP 2
- ANIX 3
- Target Price
- TNXP $585.00
- ANIX $9.00
- AVG Volume (30 Days)
- TNXP 590.0K
- ANIX 36.2K
- Earning Date
- TNXP 05-20-2025
- ANIX 06-03-2025
- Dividend Yield
- TNXP N/A
- ANIX N/A
- EPS Growth
- TNXP N/A
- ANIX N/A
- EPS
- TNXP N/A
- ANIX N/A
- Revenue
- TNXP $10,094,000.00
- ANIX N/A
- Revenue This Year
- TNXP $12.17
- ANIX N/A
- Revenue Next Year
- TNXP $789.15
- ANIX N/A
- P/E Ratio
- TNXP N/A
- ANIX N/A
- Revenue Growth
- TNXP 29.94
- ANIX N/A
- 52 Week Low
- TNXP $6.76
- ANIX $2.07
- 52 Week High
- TNXP $672.00
- ANIX $4.20
- Technical
- Relative Strength Index (RSI)
- TNXP 53.83
- ANIX 42.93
- Support Level
- TNXP $18.55
- ANIX $2.70
- Resistance Level
- TNXP $21.99
- ANIX $2.84
- Average True Range (ATR)
- TNXP 1.51
- ANIX 0.16
- MACD
- TNXP 0.27
- ANIX -0.01
- Stochastic Oscillator
- TNXP 60.18
- ANIX 25.62
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.